Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 526 to 550 of 881

TitleReference numberPublishedLast updated
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)TA576
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetesTA572
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)TA570
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Cochlear implants for children and adults with severe to profound deafnessTA566
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemiaTA561
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanomaTA562
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)TA560
Regorafenib for previously treated advanced hepatocellular carcinomaTA555
Darvadstrocel for treating complex perianal fistulas in Crohn's diseaseTA556
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemiaTA552
Lenvatinib for untreated advanced hepatocellular carcinomaTA551
Vandetanib for treating medullary thyroid cancerTA550
Decitabine for untreated acute myeloid leukaemia (terminated appraisal)TA548
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)TA549
Tofacitinib for moderately to severely active ulcerative colitisTA547
Padeliporfin for untreated localised prostate cancerTA546
Gemtuzumab ozogamicin for untreated acute myeloid leukaemiaTA545
Eltrombopag for treating chronic immune thrombocytopeniaTA293
Romiplostim for the treatment of chronic immune thrombocytopeniaTA221
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanomaTA544
Cabozantinib for untreated advanced renal cell carcinomaTA542

Results per page

  1. 10
  2. 25
  3. 50
  4. All